IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
← catalyst calendarSponsored by TuHURA Biosciences, Inc. (industry) · HURA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
9estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2025 | estimated | When the study began enrolling |
| Primary completion | 2026-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
- Drug: IFx-Hu2.0 — also filed as pAc/emm55
- Drug: Pembrolizumab — also filed as KEYTRUDA
Primary outcomes
what the primary-completion date above is the date OFSafety
measured 28 days from last dose of IFx-Hu2.0
Feasibility
measured 28 days from last dose of IFx-Hu2.0
Permalink · HURA's whole pipeline · Catalyst calendar · Every registered study · What changed